Interesting are data provided by a recent study that collected 150 enrolled patients and data concerning the preoperatory mutational status of KRAS based on the DNA of circulating tumor cells (ctDNA), studying its effect on the disease recurrence rate [47]. This evidence concerns the gene KRAS and neoplasm.